Chemcrux Enterprises Ltd

Chemcrux Q2 FY2026 Results: Standalone Revenue Hits ₹1,855.31 Lacs 📊

- Standalone revenue from operations: ₹1,855.31 lacs (Q2 FY2026)

- Standalone net profit: ₹79.95 lacs (Q2 FY2026)

- Standalone EPS: ₹0.54 (basic & diluted)

- Consolidated revenue from operations: ₹1,770.63 lacs (Q2 FY2026)

- Consolidated net profit: ₹31.39 lacs (Q2 FY2026)

- Consolidated EPS: ₹0.14 (basic & diluted)

- Standalone total assets: ₹11,272.07 lacs (Sep 30, 2025)

- Consolidated total assets: ₹12,445.72 lacs (Sep 30, 2025)

- Primary business: Manufacturing Bulk Drug Intermediates

- Subsidiary Kalichem consolidated as wholly-owned since Feb 27, 2025